Radiolabelling DOTA-peptides with 68Ga
WAP Breeman, M de Jong, E de Blois… - European journal of …, 2005 - Springer
Purpose A new field of interest is the application of 68 Ga-labelled DOTA-conjugated
peptides for positron emission tomography (PET). The commercially available or house-made …
peptides for positron emission tomography (PET). The commercially available or house-made …
68Ga-labeled DOTA-peptides and 68Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future …
WAP Breeman, E De Blois, HS Chan… - Seminars in nuclear …, 2011 - Elsevier
In this review we give an overview of current knowledge of 68 Ga-labeled pharmaceuticals,
with focus on imaging receptor-mediated processes. A major advantage of a 68 Ge/ 68 Ga …
with focus on imaging receptor-mediated processes. A major advantage of a 68 Ge/ 68 Ga …
Comparison of the therapeutic response to treatment with a 177Lu-labeled somatostatin receptor agonist and antagonist in preclinical models
…, J Nonnekens, GN Doeswijk, E de Blois… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Peptide receptor scintigraphy and peptide receptor radionuclide therapy using radiolabeled
somatostatin receptor (SSTR) agonists are successfully used in the clinic for imaging and …
somatostatin receptor (SSTR) agonists are successfully used in the clinic for imaging and …
68Ga/177Lu-NeoBOMB1, a novel radiolabeled GRPR antagonist for theranostic use in oncology
SU Dalm, IL Bakker, E de Blois… - Journal of Nuclear …, 2017 - Soc Nuclear Med
Because overexpression of the gastrin-releasing peptide receptor (GRPR) has been reported
on various cancer types, for example, prostate cancer and breast cancer, targeting this …
on various cancer types, for example, prostate cancer and breast cancer, targeting this …
Characteristics of SnO2-based 68Ge/68Ga generator and aspects of radiolabelling DOTA-peptides
E de Blois, HS Chan, C Naidoo, D Prince… - Applied Radiation and …, 2011 - Elsevier
OBJECTIVES: PET scintigraphy with 68 Ga-labelled analogs is of increasing interest in
Nuclear Medicine and performed all over the world. Here we report the characteristics of the …
Nuclear Medicine and performed all over the world. Here we report the characteristics of the …
[HTML][HTML] Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
…, E de Blois, DC van Gent, J Haeck, C de Ridder… - European journal of …, 2021 - Springer
Purpose Various radiolabeled prostate-specific membrane antigen (PSMA)–targeting tracers
are clinically applied for prostate cancer (PCa) imaging and targeted radionuclide therapy. …
are clinically applied for prostate cancer (PCa) imaging and targeted radionuclide therapy. …
Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression
…, SJ Koelewijn, E de Blois, JAN Verhaar, M de Jong… - Bone, 2014 - Elsevier
Osteoarthritis (OA) is a non-rheumatoid joint disease characterized by progressive
degeneration of extra-cellular cartilage matrix (ECM), enhanced subchondral bone remodeling, …
degeneration of extra-cellular cartilage matrix (ECM), enhanced subchondral bone remodeling, …
[HTML][HTML] Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
…, Y Seimbille, SLW Koolen, T Brabander, E de Blois - Pharmaceutics, 2021 - mdpi.com
Recently, promising results of the antitumor effects were observed in patients with
metastatic castration-resistant prostate cancer treated with 177 Lu-labeled PSMA-ligands. …
metastatic castration-resistant prostate cancer treated with 177 Lu-labeled PSMA-ligands. …
[HTML][HTML] A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues
…, ML Melis, WAP Breeman, E de Blois… - European journal of …, 2010 - Springer
Purpose Prostate-specific antigen (PSA)-based screening for prostate cancer (PC) has
dramatically increased early diagnosis. Current imaging techniques are not optimal to stage early …
dramatically increased early diagnosis. Current imaging techniques are not optimal to stage early …
[HTML][HTML] In vivo stabilization of a gastrin-releasing peptide receptor antagonist enhances PET imaging and radionuclide therapy of prostate cancer in preclinical …
…, J Nonnekens, E de Blois, S Hoeben, C de Ridder… - Theranostics, 2016 - ncbi.nlm.nih.gov
A single tool for early detection, accurate staging, and personalized treatment of prostate
cancer (PCa) would be a major breakthrough in the field of PCa. Gastrin-releasing peptide …
cancer (PCa) would be a major breakthrough in the field of PCa. Gastrin-releasing peptide …